Key result
A booster dose of S-268019-b was safe and enhanced SARS-CoV-2 neutralizing antibodies, IgG antibodies, and T-helper 1-mediated immune reactions in Japanese adults with prior mRNA vaccination.
Why the study?
Booster vaccination has become increasingly important against SARS-CoV-2 variants with immune-escaping capacity despite the initial success of primary vaccines.
Does S-268019-b booster improve immunogenicity and maintain safety in Japanese adults previously vaccinated with mRNA vaccines?
Population
Japanese adults (aged 20-64 years) and elderly (aged ≥ 65 years) primed with mRNA vaccines
Comparison
S-268019-b booster dose
Design
Phase 3 open-label clinical study
Follow-up
Day 29
Authors
Loading...
Supports S-268019-b booster immunogenicity in mRNA recipients; leaves open randomized confirmation before practice change.
Does S-268019-b booster improve immunogenicity and maintain safety in Japanese adults previously vaccinated with mRNA vaccines?
S-268019-b as a booster dose is safe and immunogenic in Japanese adults previously vaccinated with mRNA vaccines.
Sonoyama et al. (2023) studied SARS-CoV-2. S-268019-b was evaluated on Safety and immunogenicity (neutralizing antibodies, immunoglobulin G antibodies, and T-helper 1-mediated immune reaction). A booster dose of S-268019-b was safe and enhanced SARS-CoV-2 neutralizing antibodies, IgG antibodies, and T-helper 1-mediated immune reactions in Japanese adults with prior mRNA vaccination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: